Diwakar Davar
Hematology & Oncology · Pittsburgh, PANPI 1295965523
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Merck at 25.9% of the total. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $931.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$27K
- Regeneron Healthcare Solutions, Inc.$18K
- Immunocore Limited$16K
- Ascendis Pharma Endocrinology Inc$16K
- Shionogi Inc$6K
- Genmab U.S., Inc.$6K
- plus $16K from 17 others
Across 1,518 payments — averaging $14,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.9M
- GSK$5.3M
- E.r. Squibb & Sons, L.L.C.$2.7M
- Regeneron$1.8M
- AstraZeneca$1.1M
- Ascendis Pharma Endocrinology Inc$1.1M
- plus $2.8M from 11 others
What the payments were for
- Consulting fees$44,52843%
- Speaking & faculty fees$37,35836%
- Travel & lodging$18,06617%
- Food & beverage$4,3994%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 28 | $26,980 |
| Regeneron Healthcare Solutions, Inc. | 11 | $17,641 |
| Immunocore Limited | 14 | $16,267 |
| Ascendis Pharma Endocrinology Inc | 9 | $15,635 |
| Shionogi Inc | 4 | $5,990 |
| Genmab U.S., Inc. | 1 | $5,950 |
| Trisalus Life Sciences, Inc. | 4 | $4,527 |
| Sanofi | 1 | $3,245 |
| Eisai Inc. | 1 | $1,785 |
| Regeneron | 12 | $1,781 |
| E.r. Squibb & Sons, L.L.C. | 6 | $1,558 |
| GSK | 2 | $1,350 |
| Clinigen, Inc. | 3 | $380 |
| Iovance Biotherapeutics, Inc. | 2 | $274 |
| Novartis | 4 | $207 |
| GE HealthCare | 2 | $204 |
| AbbVie | 1 | $139 |
| Delcath Systems | 1 | $125 |
| Amgen | 1 | $101 |
| AstraZeneca | 1 | $78 |
| Tesaro, Inc. | 2 | $76 |
| Array Biopharma Inc | 1 | $55 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$9,648
- TRINAV INFUSION SYSTEM$4,497
- LIBTAYO$3,111
- LENVIMA$1,785
- KEYTRUDA$310
- Proleukin$290
- Amtagvi$274
- ALLODERM$139
- Hepzato Kit$125
How this compares
$104,362 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 55 | $2,149 |
| Oxycodone Hcl | 23 | $268 |
| Levothyroxine Sodium | 25 | $254 |
| Prednisone | 40 | $138 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
- Stanley MarksPittsburgh$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.